Wikipedia
Anacor Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It is based in Palo Alto, California, United States. Anacor was founded in 2002 based on technology created by Lucy Shapiro at Stanford University and Stephen Benkovic at Pennsylvania State University. Cofounder David Perry served as CEO and President from 2002 to 2014, and took the company public in 2010. Since then, the company has generated a pipeline of both topical and systemic boron-based compounds of which five are currently in clinical development.
In May 2016, Pfizer announced it would acquire Anacor Pharmaceuticals for $5.2 billion, expanding the company's portfolio in both inflammation and immunology drugs areas.